On January 19, 2022, the analgesic drug JUPOPHON® (Ibuprofen Sustained-Release Capsules) officially passed the Generic Drug Consistency Evaluation.

Consecutive Wins in National Centralized Procurement
RoToFier®Glipizide Extended ReleaseTablets

June 2021   Selected in the 5th Round of National Centralized Drug Procurement.

April 2023   Re-selected in the 16-Province Alliance (Henan-led) Continuation Procurement Project for the 3rd and 5th Batch Drugs.

Covered provinces: Henan, Hebei, Shanxi, Inner Mongolia, Liaoning, Jilin, Heilongjiang, Hubei, Hunan, Hainan, Qinghai, Ningxia, Xinjiang, Guizhou.

May 2023   Selected in Fujian Province’s Volume-Based Continuation Procurement Project for Batches 1–5.

Covered province: Fujian.

July 2023   Re-selected in the Interprovincial Alliance Continuation Procurement for Expired National Centralized Procurement Products.

Covered provinces: Jiangsu, Shaanxi, Guangxi.

August 2023   Selected in in the Shanghai 15-Province Volume-Based Procurement Alliance.

Primary supply regions: Shanghai, Beijing, Shandong, Jiangxi, Sichuan.

Alternate supply regions: Yunnan, Zhejiang, Anhui, Chongqing, Gansu, Tianjin, Tibet.

April 2024   Re-selected in Guangdong Province’s Volume-Based Procurement Project for Tinidazole and Other Drugs.

Covered province: Guangdong.

JUPOPINE®Nifedipine Controlled-ReleaseTablets

July 18, 2022   Selected in the 7th Round of National Centralized Drug Procurement.

The procurement cycle for this round is still ongoing and is expected to conclude by the end of 2025, at which point a follow-up procurement initiative will be launched.

JUPOSHU®Amlodipine Besylate Tablets

October 2022  Selected in the Chongqing Alliance Continuation Procurement for the 1st and 3rd Round of National Volume-Based Drug Procurement.

Covered provinces: Chongqing, Sichuan, Inner Mongolia, Hubei, Tibet, Shaanxi, Yunnan.

April 2023Re-selected in Henan Province’s Volume-Based Linked Procurement for Clopidogrel Oral Formulations and other drugs.

Covered province: Henan.

June 2023Re-selected in the Continuation Procurement for the 2022 1st, 2nd, and 4th Batch National Centralized Procurement Drugs; directly renewed in 2023.

Covered province: Beijing.

July 2023Re-selected in the Interprovincial Alliance Continuation Procurement for Expired National Centralized Procurement Products.

Covered province: Jiangsu.

February 2024Re-selected in the Guangdong Alliance Volume-Based Procurement for Amoxicillin and Other Drugs.

Covered provinces Guangdong, Hunan, Guizhou, Gansu, Ningxia, Shanxi, Guangxi, Xinjiang, Hainan, Qinghai.

JUPOPHON® Ibuprofen Sustained-Release Capsules

January 2024Re-selected in the Jiangsu-Shaanxi Alliance Continuation Procurement Project for expired National Centralized Procurement drugs.

Covered provinces: Jiangsu, Shaanxi.

May 2024Re-selected in Shandong Province’s Volume-Based Procurement for drugs with expired agreements.

Covered province: Shandong.

May 2024Re-selected in the Henan 13-Province Alliance Volume-Based Procurement.

Covered provinces: Henan, Guizhou, Jilin, Guangxi, Qinghai, Xinjiang, Hainan, Ningxia, Shanxi, Inner Mongolia, Heilongjiang, Liaoning.

April 2025Re-selected in the Guangdong Alliance Volume-Based Procurement for Apixaban and other drugs.

Covered provinces: Guangdong, Jiangxi, Yunnan, Anhui, Sichuan, Chongqing, Gansu, Fujian, Hubei, Hunan, Tibet